Martini, Alberto http://orcid.org/0000-0001-7642-1459
Lovell, Daniel J. http://orcid.org/0000-0003-1604-0130
Albani, Salvatore
Brunner, Hermine I. http://orcid.org/0000-0001-9478-2987
Hyrich, Kimme L. http://orcid.org/0000-0001-8242-9262
Thompson, Susan D. http://orcid.org/0000-0003-4130-2796
Ruperto, Nicolino http://orcid.org/0000-0001-8407-7782
Article History
Accepted: 13 December 2021
First Online: 27 January 2022
Competing interests
: A.M. has received honoraria for consultancies or speaker bureaus from Aurinia, Bristol Myers Squibb, Eli Lilly, EMD Serono, Janssen, Pfizer and Roche. D.J.L.’s institution, the Cincinnati Children’s Hospital Medical Center, has received research grants from BMS, Janssen, Novartis, Pfizer Inc., Roche and UBC; and has received consulting fees or other remuneration from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer Inc., Roche, Takeda and UBC for the work of D.J.L. D.J.L. is a member of the Data Safety and Monitoring Boards for studies funded by the National Institutes of Health and the Canadian Arthritis Society. H.I.B. received speaker fees from Novartis, Pfizer, Roche and GlaxoSmithKline. The Cincinnati Children’s Hospital, where H.I.B. works as a full-time employee, has received contributions from the following companies for consultation and research activities in the past 3 years: AbbVie, AstraZeneca–MedImmune, Biogen, Boehringer, Bristol Myers Squibb, Celgene, Eli Lilly, EMD Serono, Idorsia, Cerocor, F. Hoffmann-La Roche, Merck, Novartis and Sanofi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties. K.L.H. has received honoraria from Abbvie and grant support from Pfizer and Bristol Myers Squibb. K.L.H. is also supported by the NIHR Biomedical Research Centre. S.D.T. is supported by Cincinnati Children’s Research Foundation and the US National Institutes of Health. N.R. has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2-Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Lilly, Novartis, Pfizer, Sobi, UCB. S.A. declares no competing interests.